Comparing the current results to its competitors, Caredx Inc reported Revenue increase in the 1 quarter 2026 by 38.99 % year on year. The sales growth was above Caredx Inc 's competitors' average revenue growth of 13.37 %, achieved in the same quarter.
Strong sales growth of 38.99 % in Overall company contributed to Caredx Inc increase in total revenue by 38.99 % Caredx Inc improved its market share in this segment, to approximately 3.37 %.
August 1, 2025
In the realm of transplant diagnostics, CareDx, Inc., headquartered in Brisbane, California, has emerged as a trailblazer, showcasing its commitment to precision medicine with impressive results at the 2025 World Transplant Congress (WTC). With over 40 abstracts and 16 oral presentations presented by independent research teams, CareDx has reinforced its reputation as a leader in developing high-value healthcare solutions tailored for transplant patients and their caregivers.The company s advancements in artificial intelligence (AI) power diagnostics, which were a key focus of the congress, accentuate their ongoing efforts to harness technology for improved patient outcomes. Unlike many competitors within the...
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
MDxHealth SA is a biotech company that primarily focuses on developing and commercializing molecular diagnostic tests to assist healthcare professionals in making informed treatment decisions for cancer patients. Their business model revolves around providing accurate and actionable diagnostic information to improve patient outcomes and potentially reduce healthcare costs.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Sources:
Caredx Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Caredx Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
